In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

Over the last five years, the stock has decreased in 56% of these instances, with a median decline of -3.1% and a maximum ...